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Observations of Psoriasis in the Absence of
Therapeutic Intervention Identifies Two
Unappreciated Morphologic Variants, Thin-Plaque
and Thick-Plaque Psoriasis, and their Associated
Phenotypes
Tanya E. Christensen1, Kristina P. Callis1, Jason Papenfuss1,2, Matthew S. Hoffman1,
Christopher B. Hansen1,3, Bob Wong1, Jacqueline M. Panko1 and Gerald G. Krueger1
Psoriatic plaque thickness is a clinical measure of psoriasis severity. We have observed that patients tend to
revert to a baseline thickness of psoriatic plaques when in an untreated state, and hypothesized that other
features of psoriasis could associate with this trait. Data prospectively collected on 500 participants in the Utah
Psoriasis Initiative were used for the study. In response to a question assessing plaque thickness when disease
was at its worst, 144 (28.8%) reported thick plaques, 123 (24.6%) reported thin plaques, and 233 (46.6%) reported
intermediate thickness. For patients with ‘‘worst-ever’’ disease at enrollment (n¼ 122), there was significant
correlation of thickness between assessment by the patient and the physician (r¼ 0.448, P-value 0.01). Thick
plaques associated with male gender, increased body mass index, nail disease, psoriatic arthritis, larger plaques,
more body sites, and greater total body surface area affected. Thin plaques associated with eczema, guttate
psoriasis, and skin cancer. We suggest that this is preliminary evidence that plaque thickness is an easily
measured trait that associates with other clinical features of psoriasis, and that stratification on this phenotype
may be useful in further defining the genetic basis of this disease.
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INTRODUCTION
Psoriasis is a common, multifactorial skin disorder that affects
approximately 2–3% of the United States population. The
search for the psoriasis gene or genes continues; although
linkage to several loci have been proposed, none have a
linkage to the pathogenesis of this disorder(Capon et al.,
2004; Griffiths, 2004; Sagoo et al., 2004). The difficulty in
linking psoriasis to a single gene has magnified the necessity
of defining and stratifying psoriasis into phenotypic variants.
It is generally presumed that genes control subtypes or
features of psoriasis; that is, genotype predicts phenotype.
Historically, the classic subtypes of psoriasis have been
described as erythrodermic, guttate, pustular, palmar/plantar,
and plaque type. However, it is probable that plaque-type
psoriasis, the most common subtype of psoriasis, is composed
of a variety of subtypes (Christophers, 2003; Griffiths, 2004).
Different arrays of characteristics such as plaque location,
concurrent nail disease, psoriatic arthritis, plaque appearance
(size, thickness, shape, erythema, scale), response to envir-
onment or treatment, and course of disease may represent
distinct clinical entities under the umbrella of ‘‘psoriasis’’.
The Utah Psoriasis Initiative (UPI) was established to study
and classify subtypes of psoriasis based upon observable and
patient-reported characteristics to facilitate the correlation of
psoriasis phenotypes with genotype. In clinics specializing in
the care and management of psoriasis, the senior authors
(GGK and KPC) have repeatedly observed that patients with
plaque-type psoriasis vulgaris tend to have a baseline
(defined as no therapeutic intervention) plaque appearance,
with a usual thickness and size that is characteristic for them.
It is readily acknowledged that while time and treatment may
clear or improve disease, we hypothesize that psoriatic
plaques have a baseline appearance in an untreated state. In
this study, we classified patients based on plaque thickness in
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the untreated (worst-ever) state and to describe the associated
phenotypic features of patients with three different levels of
thickness, thin, intermediate, and thick. To our knowledge,
this is the first description of the associated phenotypic
features of thin versus thick-plaque psoriasis. This distinction
may be important in future studies performed to associate
genotype and phenotype.
RESULTS
Of the 539 participants, 500 (93%) enrolled in the UPI were
included in the analysis. Of the 39 that were excluded, 24 did
not have plaque-type psoriasis (most reported isolated
palmar/plantar disease), and for 15 the exam registry forms
were not completed. Of the 500 participants analyzed, 144/
500 (28.8%) reported thick plaques when psoriasis thickness
was at its worst, 123/500 (24.6%) reported thin plaques, and
233/500 (46.6%) reported intermediate.
Comparison of physician and patient thickness groups
Two separate comparisons measures were completed to
verify the patient-reported worst psoriasis plaque thickness
(Figure 1). First, a comparison between the physician
induration score and patient-reported worst psoriasis plaque
thickness was made. The analysis used only patients who
were at least 80% of their ‘‘worst-ever psoriasis’’ at
enrollment (patient global assessment) score 4 or 5)
(n¼122, 24.4%). The mean physician induration score for
patients in this worst ever at enrollment cohort who rated
their plaques as ‘‘thick’’ was 2.870.2 SEM, for ‘‘thin’’ was
1.370.1 SEM, and for ‘‘intermediate’’ was 2.070.1 SEM.
The mean scores demonstrated significant differences
(Po0.0001). Pearson’s bivariate correlation between patient
and physician scores was 0.448 (P¼ 0.01). Second, a
retrospective chart review on those patients in the UPI who
had participated in a prior clinical study was performed to
determine if reported plaque thickness was similar to
physician determined plaque induration scores from previous
years. Both National Psoriasis Foundation (NPF) induration
card scores and the induration component of the psoriasis
assessment scales (PASI) score were compared to patient-
reported thickness. Of the 500 participants, 34 (6.8%) of the
UPI had been part of a previous clinical drug study, which
recorded NPF induration scores at baseline. The mean score
for thick (n¼19), 2.670.2 SEM, was significantly different
than the mean score for intermediate (n¼14), 1.970.5 SEM
(P¼0.024), but not from the mean score for thin (n¼ 1),
1.070.0 SEM (P¼0.067). 58/500 (11.6%) UPI participants
had been part of a previous clinical study which recorded
PASI scores at baseline. The mean PASI induration score for
thick, 2.570.1 SEM, was significantly different than the mean
score for thin 1.770.2 SEM (P¼ 0.027), and also significantly
different than the mean score for those intermediate,
2.370.1 SEM (P¼ 0.023).
Phenotypic differences between thickness groups
Demographic and disease differences between thick, thin,
and intermediate groups are in Table 1. No significant
difference was found between groups in ethnicity, age at
enrollment, age of onset, disease duration, positive family
history, treatment status at enrollment, smoking, alcohol use,
or reported Koebner phenomenon. There was also no
association between thickness and other psoriasis diagnoses,
except for guttate psoriasis, which was more commonly
reported in the thin (16.3%) and intermediate (18.5%) groups
than in the thick group (7.6%) (P¼0.014).
Participants who reported thick-plaque psoriasis were
more likely to be male (59% thick, versus 51.9% intermediate
versus 41.5% thin, P¼ 0.014). There was also a significantly
increased prevalence of psoriatic arthritis (P¼0.0005),
psoriatic nail disease (P¼0.001), and larger plaques
(P¼0.001) in participants with thicker disease.
Although there was no significant difference in age of
onset overall, when segregated by gender, the age of onset for
males was significantly different between groups (analysis of
variance, F¼5.7, P¼0.004). The mean age of onset in years
for males with thin-plaque psoriasis, 35.0718.5, was
significantly higher than the mean age of onset for males
with intermediate, 28.9715.9 (P¼ 0.049), and thick,
25.9712.8 (P¼ 0.002).
Figure 2 shows the differences in the median percent body
surface area (BSA) affected for thin, intermediate, and thick-
plaque psoriasis. Physician-reported BSA upon enrollment
correlated closely with patient-reported BSA upon enrollment
(r¼0.882, Po0.0001). Patients with thick-plaque psoriasis
had significantly more body surface affected on enrollment









Patient reported worst plaque thickness
Thick
Figure 1. Validation of patient-reported plaque thickness: each marker
represents the mean7SEM NPF induration score. W, Mean physician
recorded NPF induration card scores versus patient-reported psoriasis plaque
thickness when at its worst for only those participants who reported a patient
global assessment of 4 (80% of worst ever) or 5 (100% of worst ever) upon
study entry (n¼ 122/500). Analysis of variance (F¼ 15.0, Po0.0001) showed
significant differences between thick–thin (Po0.0001) and thick–intermediate
(P¼0.0001). &, Mean NPF induration card score from chart review of
baseline visits from clinical trials from 2001 to 2003. Analysis of variance
for NPF (F¼ 5.8, P¼0.007). Thin–thick differences (P¼ 0.067);
thick–intermediate (P¼0.024), and thin–intermediate (P¼0.376).
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for patient-reported BSA, Po0.0001 for physician-reported
BSA; Mann–Whitney test between groups, all P-values
o0.02). Patient-reported worst-ever BSA was significantly
higher for thick plaque participants (median 15%, range
1–100%) than for either intermediate (median 7%, range
1–99%) or thin (median 6%, range 1–96%) (Kruskal–Wallis
Po0.0001; Mann–Whitney test for thin–thick, P¼0.0003,
thick–intermediate, Po0.0001, and thin–intermediate,
P¼0.633).
Association with other conditions
Table 2 lists 16 other medical conditions with a prevalence
45% within the sample. Eczema had a marginally significant
P-value (0.014) with a greater frequency in thin plaque
(17.1%) than in either intermediate (7.3%) or thick (13.9%).
Skin cancer was reported significantly more frequently in
participants with thin-plaque psoriasis (19.5%) than in those
with intermediate (9.4%) or thick (4.9%) (P¼0.0004). The
rest of the disease listed in Table 2 either had nonsignificant
P-values for differences between thickness groups or the
sample size was to small to assess an effect.
DISCUSSION
Classification of the clinical features of psoriasis has been a
controversial subject among investigators. Defining presence
or absence of psoriatic arthritis, nail disease, what constitutes
‘‘early onset’’ of disease, and even certainty of the diagnosis
of psoriasis are challenging tasks for the clinician when
Table 1. Demographic and disease data for patient-reported worst psoriasis plaque thickness
Sample (n=500) Thin (n=123) Intermediate (n=233) Thick (n=144) P-value
Gender 0.014
Male 248 (49.6) 51 (41.5) 112 (48.1) 85 (59)
Female 252 (50.4) 72 (58.5) 121 (51.9) 59 (41)
Ethnicity
White/Caucasian 465 (93) 119 (96.7) 213 (91.4) 133 (92.4) 0.068
Age at enrollment (years) 49.5716.5 (50) 51.5718.9 (54) 48.9716.0 (49) 48.8715.0 (50) 0.303
Age onset (years) 27.2716.4 (23) 29718.5 (23) 27716.7 (24) 26713.8 (23) 0.321
Male 29.1715.6 35.0717.3 (30) 28.9715.9 (26.5) 25.9712.8 (22.0) 0.004
Female 25.3717.0 24.7718.1 (19) 25.2717.2 (20) 26.2 15.1 (23) 0.880
Disease duration (years) 22.3715 (19) 22.5715.6 (19) 21.9714.6 (18) 22.8715.0 (21) 0.836
BMI (kg/m2) 29.277.4 (27.9) 27.375.4 (26.5) 29.477.5 (27.9) 30.678.2 (28.8) 0.001
Family history positive 331 (66.2) 80 (65) 162 (69.5) 89 (61.8) 0.291
Currently treated 410 (82.5) 94 (77) 194 (83.6) 122 (85.3) 0.174
Smoking 186 (37.2) 40 (32.5) 83 (35.6) 63 (43.8) 0.132
Alcohol 171 (34.2) 37 (30.1) 79 (33.9) 55 (38.2) 0.376
Koebner phenomenon 211 (42.2) 44 (35.8) 99 (42.5) 68 (47.2) 0.167
Nail disease 304 (62.2) 65 (53.7) 134 (59) 105 (74.5) 0.001
Psoriatic arthritis 136 (27.4) 19 (15.6) 64 (27.6) 53 (37.1) 0.0005
Size of plaques
Small, scattered plaques 183 (36.7) 82 (66.7) 73 (31.3) 28 (19.6) o0.0001
Mix of both 217 (43.5) 31 (25.2) 129 (55.4) 57 (39.9) —
Large, geographic plaque type 99 (19.8)g 10 (8.1) 31 (13.3) 58 (40.6) —
Other diagnoses other than plaque-type
Erythrodermic 7 (1.4) 1 (0.8) 4 (1.7) 2 (1.4) 0.788
Guttate 74 (14.8) 20 (16.3) 43 (18.5) 11 (7.6) 0.014
Generalized pustular 12 (2.4) 2 (1.6) 8 (3.4) 2 (1.4) 0.367
Inverse 141 (28.2) 34 (27.6) 69 (29.6) 38 (26.4) 0.786
Only palmar/plantar disease 15 (3) 2 (1.6) 10 (4.3) 3 (2.1) 0.279
Palmar/plantar pustulosis (PPP) 11 (2.2) 2 (1.6) 7 (3) 2 (1.4) 0.514
ANOVA, analysis of variance; BMI, body mass index.
For categorical variables, data presented as number (%) and P-values calculated from w2 test. For continuous variables, data presented as mean7SD
(median) and P-values calculated from ANOVA.
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findings are subtle. It has been our belief that classification of
phenotypic features such as plaque thickness is possible and
may lead to genetic associations and better understanding of
psoriasis. Stratification by phenotype has already led to the
identification of susceptibility loci in numerous studies
(Samuelsson et al., 1999; Allen et al., 2005; Karason et al.,
2005).
In this study, we present data suggesting that plaque
psoriasis can be classified by its thickness, that patient
self-report of thickness correlates with physician induration
scores, and that some phenotypic features of psoriasis
associate with plaque thickness. Subjects with thick-plaque
psoriasis have significantly more nail disease, psoriatic
arthritis, larger plaques, more BSA affected, and are more
likely to be male than are their counterparts with thin-plaque
psoriasis. Although plaque induration is a part of most PASI
(NPF Psoriasis Score), to our knowledge, there are no
previous studies comparing inherent phenotypic differences
across plaque thickness.
Thickness validity
A chronic challenge has been designing a sensitive tool to
detect and segregate phenotypic differences within psoriasis.
The question posed to our patients asking them to describe
the thickness of their plaques when at their worst is an
attempt to capture a reasonably accurate description of a
disease process at a single point in time. Participants were in
varying states of disease flare or remission upon enrollment.
Our data are therefore subject to significant recall bias. To
assess appearance of psoriasis plaques when at their worst,
we relied on patient report with assistive measures including
the NPF induration card and standard photos, which also
have limitations. Determination of induration, even by
investigators trained to do psoriasis assessments for clinical
trials, is an inexact science in the absence of an objective
measure. Use of the NPF induration card was therefore
instituted to assist with the induration assessments. This card
is consistently used as part of the NPF Psoriasis Score, which
has been validated against PASI in clinical trials where both
scoring systems were used as end points. Although the card
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Figure 2. Comparison of median percent total BSA between
patient-reported worst psoriasis plaque thicknesses. Significant
differences between groups by Kruskal–Wallis for worst-ever BSA
(P¼0.0001), physician BSA (Po0.0001), and patient BSA (Po0.0001).
Physician BSA¼ physician-reported total BSA affected at the time of
examination; patient BSA¼ patient-reported total BSA affected at the time of
examination; worst-ever BSA¼ patient-reported worst-ever total body surface
affected.
Table 2. Disease prevalence by thickness for diseases with a prevalence 45% in the sample
Sample (n=500) Thin (n=123) Intermediate (n=233) Thick (n=144) P-value* Pc-value
**
Arthritis 169 (33.8) 40 (32.5) 76 (32.6) 53 (36.8) 0.665 NS
High blood pressure 141 (28.2) 36 (29.3) 59 (25.3) 46 (31.9) 0.364 NS
Depression 110 (22) 28 (22.8) 51 (21.9) 31 (21.5) 0.969 NS
High cholesterol 101 (20.2) 20 (16.3) 51 (21.9) 30 (20.8) 0.442 NS
Migraine headaches 70 (14) 20 (16.3) 35 (15) 15 (10.4) 0.323 NS
Eczema 58 (11.6) 21 (17.1) 17 (7.3) 20 (13.9) 0.014 NS
Diabetes 53 (10.6) 7 (5.7) 25 (10.7) 21 (14.6) 0.063 NS
Skin cancer 53 (10.6) 24 (19.5) 22 (9.4) 7 (4.9) 0.0004 0.013
Anemia 49 (9.8) 9 (7.3) 21 (9) 19 (13.2) 0.235 NS
Asthma 43 (8.6) 9 (7.3) 21 (9) 13 (9) 0.843 NS
Irritable bowel disease 43 (8.6) 10 (8.1) 21 (9) 12 (8.3) 0.952 NS
Thyroid disease 41 (8.2) 13 (10.6) 18 (7.7) 10 (6.9) 0.525 NS
Seborrheic dermatitis 37 (7.4) 11 (8.9) 20 (8.6) 6 (4.2) 0.212 NS
Recurrent strep throat 35 (7) 11 (8.9) 16 (6.9) 8 (5.6) 0.554 NS
Cancer 28 (5.6) 8 (6.5) 16 (6.9) 4 (2.8) 0.216 NS
NS, nonsignificant.
*P-value from w2 test.
**Pc: corrected P-value for 32 multiple comparisons.
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pilot study at three centers, we demonstrated a trend toward
improved intra-observer reliability when investigators used
the card.1
Regardless, our data show that the patient’s assessment of
plaque thickness at UPI enrollment is comparable to the PASI
and NPF induration assessments at enrollment of clinical
trials in the past when the patient had typically not been
treated for 2–4 weeks during a ‘‘wash-out’’ period. In
addition, for those patients who were at their worst at
enrollment, the physician-recorded mean NPF score corre-
lated significantly with patient report.
Association of plaque thickness with clinical phenotypes
The associations that we found between thick plaques and
clinical features of psoriasis including nail disease, psoriatic
arthritis, and male gender are corroborated by previously
described phenotypic variants. Nail disease and psoriatic
arthritis have been shown to be markers for more severe
psoriasis, and they have also been shown to occur in
association with one another (Williamson et al., 2004).
Males have also been shown to have psoriatic arthritis at a
ratio of 1.3:1 to females (Taylor, 2002). Changes in epidermal
thickness correlate with disease improvement as measured by
PASI (Gottlieb, 2003).
The argument can be made that thick-plaque psoriasis is
simply a marker of more severe disease. However, disease
severity remains difficult to classify and is most often used in
clinical trials as measures of improvement, or in the clinic to
determine appropriate aggressiveness of therapy and often in
conjunction with insurance definitions. Studies that have
stratified patients on psoriatic arthritis and nail disease have
yielded new minor genetic susceptibility loci (Samuelsson
et al., 1999; Karason et al., 2005). We propose that the
classification of plaque thickness and its relationship to
psoriatic arthritis and nail disease requires further genome-
based investigation.
Our findings show that thin-plaque psoriasis was asso-
ciated with a reported history of guttate psoriasis, with a
reported history of eczema, and with an increased prevalence
of skin cancer when compared with those with thick-plaque
psoriasis. These associations are subject to recall bias and
potential past misdiagnosis of conditions such as guttate
psoriasis or eczema that is inherent and cannot be readily
eliminated. The association of thin plaque disease with
guttate psoriasis is very interesting as it is known that guttate
psoriasis has a high association with the major genetic
psoriasis susceptibility locus, HLA-Cw6 (Asumalahti et al.,
2003). Atopic dermatitis is associated with numerous loci
in common with psoriasis (Bowcock and Cookson, 2004).
Our observation of thin plaque disease associating with
atopic diatheses needs to be replicated and assessed in a
cohort that is to be followed longitudinally. With this in hand
a more complete association analysis can be carried out
to determine if the genes/gene-sets that give rise to the
aptopic diathesis also have a role in the presentation of thin
plaque disease.
Environmental explanations may better explain the asso-
ciation between thin-plaque psoriasis and skin cancer. It is
plausible that thin plaque participants may have been treated
with more light therapies; it is known that an increased
exposure to psoralen UVA increases the incidence of
squamous cell carcinomas in psoriasis patients (Stern and
Lunder, 1998). A second possibility is that subjects with
thick-plaque psoriasis are inherently more resistant to skin
cancer. A recent study showed that patients with psoriasis
may have fewer actinic keratoses (Paltiel et al., 2004), and
hence a decreased likelihood of developing non-melanoma
skin cancers. Nickoloff (2004) proposes that psoriatic plaques
are resistant to developing skin cancer owing to UV light
triggering senescence in keratinocytes of psoriatic plaques. As
thick-plaque psoriasis patients had more BSA affected in our
cohort, they are possibly less likely to develop skin cancer
than thin plaque patients simply because they have more
plaques inherently resistant to skin cancers.
Limitations
As discussed above, our study has limitations. A major
component of the UPI database relies on patient self-report
and thus has an inherent recall bias. Patient classification of
plaques or BSA, even with assistive measures, as well as
physician induration scores are not objective measures;
however, the ‘‘gold standard’’ of biopsying and photograph-
ing every patient is impractical and is not even performed in
clinical trials. Determining presence or absence of nail
disease and psoriatic arthritis also are areas of controversy.
We did not have a rheumatologist confirm every case of
psoriatic arthritis, and although we are very certain that we
have not excluded patients with psoriatic arthritis, we may
have included some patients with overlap, that is, they have
both an inflammatory arthritis and a degenerative arthritis,
and thus it is possible that misclassification of arthritis could
have skewed our results. Nevertheless, using our study
physicians, we have established an incidence of psoriatic
arthritis of 27.4%, which is in line with previously published
studies (Farber and Nall, 1974; Stuart et al., 2002).
Conclusion
As the elucidation of the genetics of psoriasis continues, the
phenotypic stratification of subtypes of psoriasis becomes
increasingly important. Several studies have described
phenotypic differences in psoriasis based on characteristics
such as early and late age of onset (Henseler and
Christophers, 1985; Swanbeck et al., 1995; Ferrandiz et al.,
2002), facial psoriasis (Young Park et al., 2004), or family
history (Stuart et al., 2002). The association between genetics
and phenotype has been studied within and near HLA-Cw6
(Henseler and Christophers, 1985; Gudjonsson et al., 2002;
Asumalahti et al., 2003; Gudjonsson et al., 2003), for large-
and small-plaque psoriasis (Lew et al., 2004) and for psoriatic
arthritis (Gudjonsson et al., 2003). Ultimately, genome-based
studies will determine the validity of stratification on
morphological variants, such as thin- and thick-plaque
psoriasis. It is our hope that genotype–phenotype associations
will not only help elucidate the genetics of psoriasis but
may also help predict response to treatment and relapse
probability over time.
www.jidonline.org 2401
TE Christensen et al.
Psoriasis: Plaque Thickness Defines a Phenotype
MATERIALS AND METHODS
The UPI was designed to collect phenotypic information on psoriasis
patients to stratify phenotypes for more informative genotyping. The
study was approved by the University of Utah Institutional Review
Board, and patients enrolled from November 2002 to July 2004 were
included in this analysis. All volunteers gave written informed
consent, and the study was conducted according to the Declaration
of Helsinki Principles. Patients were recruited through the dermato-
logy clinics affiliated with the University of Utah and other
dermatology clinics in the greater Salt Lake City area. Only those
patients with confirmed psoriasis by Drs Krueger, Callis, or a trained
research fellow, Drs Hansen or Papenfuss, were enrolled. The study
enrollment procedure consisted of three parts. First, patients
completed an enrollment questionnaire. Next, the patient was
examined and questioned by a trained physician using a structured
exam registry form. Last, DNA was isolated from peripheral blood
and stored for future genotype analysis.
Questions pertinent to this study in the patient enrollment
questionnaire included gender, identifying information, age, ethni-
city, medical history (including other medical conditions), smoking,
alcohol, family history, age of onset, and diagnosis, description of
psoriasis when it first appeared, factors that improve or worsen their
psoriasis, history of Koebner phenomenon (developing psoriasis at
sites of skin injury), and typically affected body parts. The patient
was queried using descriptions and specific questions as to
determine whether they had a history of guttate, erythrodermic,
generalized pustular, palmar/plantar pustular, only palmar/plantar
disease (defined as at any time having only their palms and/or soles
affected), or inverse psoriasis (defined as having any psoriasis at any
time in the body folds, including the axilla, beneath the breast,
abdominal folds, inguinal folds, or gluteal folds).
Psoriatic nail disease was determined by physician exam of the
fingernails. Onycholysis, pitting (total ofX5 pits on fingernails) (Rich
and Scher, 2003), subungual hyperkeratosis, and dystrophy were
considered signs of nail disease. The patient was considered to have
psoriatic arthritis based on the following criteria: (1) either the
patient had been diagnosed as having psoriatic arthritis by a
rheumatologist or (2) the patient presented with symptoms of an
inflammatory arthritis and not those of degenerative arthritis and had
evidence of enthesitis, morning stiffness lasting one hour or more,
sacroiliac pain, characteristic joint deformities of the fingers and
toes, and/or pauciarticular disease of the large joints.
BSA was determined by the palm method (the palm to the
proximal interphalangeal joint, including the thumb, of the patient
E1% of the total BSA). The patient was asked to estimate their total
BSA on enrollment and then to estimate their worst-ever BSA. The
physician also assessed BSA on enrollment.
At enrollment, the physician recorded the severity of present
lesions using the NPF Psoriasis Score, described elsewhere (Krueger
et al., 1999). Induration was scored from NPF induration score
card, which has embossed elevations from 0 to 1.25 mm, where
0¼ 0 mm, 1¼ 0.25 mm, 2¼ 0.50 mm, 3¼ 0.75 mm, 4¼ 1.0 mm,
and 5 X1.25 mm. Patient global assessment at enrollment was
based on a scale of 0–5 with 0¼ no psoriasis; 1¼ 20% as bad as
ever; 2¼ 40% as bad as ever; 3¼ 60% as bad as ever; 4¼ 80% as
bad as ever; and 5¼ the worst their psoriasis has ever been. To
determine the appearance of psoriasis at its worst, patients were
asked to describe the typical erythema, scale, and induration of their
worst untreated lesions. For this assessment, a standard set of
photographs was given to the patients and the patient was asked to
score their disease for erythema (0–5) and scale (0–5) based on the
photograph that most closely resembled their psoriasis when at its
worst. Induration of psoriasis plaques when at their worst was
determined by asking the patient to describe their psoriasis at its
worst as ‘‘thick, indurated plaques with tenacious, thick scale’’,
‘‘thin plaques, light pink, with fine scale’’, or ‘‘in between the above
(intermediate)’’. Two analyses were performed to compare the
physician induration score and patient-reported psoriasis plaque
thickness. For those patients where at least 80% of their ‘‘worst-ever
psoriasis’’ at enrollment (PGA score 4 or 5), a physician NPF
induration score was performed at enrollment using the NPF card.
The mean physician induration score was determined again for each
patient thickness group; additionally, a Pearson’s univariate correla-
tion was performed between the physician and patient scores. Third,
a retrospective chart review on those patients in the UPI who were in
a prior clinical study where the PASI and/or NPF Psoriasis Score was
performed. Prior NPF induration scores of 0–1 were considered
‘‘thin’’, 2 was considered ‘‘intermediate’’, and 3, 4, or 5 considered
‘‘thick’’; prior PASI induration scores of 0–1 considered ‘‘thin’’, 2
was considered ‘‘intermediate’’, and 3 or 4 considered ‘‘thick’’.
Mean physician induration scores were again averaged for each of
the three patient thickness groups and compared using analysis of
variance.
Statistical analysis
Thin, intermediate, and thick groups were compared across
continuous and categorical variables. Categorical variables were
compared using w2 test. For continuous parametric variables,
analysis of variance was used with the Tukey’s post hoc comparison
to determine if any significant differences existed between each of
the groups. For non-parametric continuous variables, the Kruskal–-
Wallis and Mann–Whitney test was used. Data were presented as
mean7SD, except where specified in the results section. Pearson’s
correlation coefficients were calculated for the correlation analysis
of BSA and for correlation analysis of patient and physician
induration scores. The Cramer V correlation statistic was reported
for the validation analyses (i.e., comparing thickness groups to
physician-reported NPF scores and previous induration scores).
P-values less than 0.05 were considered significant, except for the
comparison of other diseases between thickness groups (see Table 2),
where the Bonferoni correction was used for multiple comparisons.
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